Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of medicine for treating megaloblastic liver cancer

A composition and a bulk-type technology, applied in the field of medicine, can solve the problems of large resection range, liver insufficiency, difficult operation, etc., and achieve the effects of prolonging the survival period, relieving the disease, and benefiting the patient.

Pending Publication Date: 2022-01-07
THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to imaging results, massive liver cancer refers to a special type of liver cancer with a tumor diameter ≥ 5 cm. Because the tumor is huge, it is often located close to important areas such as the hilum of the liver, oppressing and invading large blood vessels inside and outside the liver, making surgery difficult; at the same time , the surgical resection range is large, and the risk of postoperative hepatic insufficiency is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of medicine for treating megaloblastic liver cancer
  • Combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of medicine for treating megaloblastic liver cancer
  • Combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of medicine for treating megaloblastic liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] The embodiment of the application provides the combined treatment effect and safety evaluation of case 1:

[0042] see figure 1 , figure 1 The results before and after treatment of case 1 provided in the embodiment of the present application.

[0043] The MR results on January 5, 2021 showed a huge oval mass in the right lobe of the liver at S5 / S6, about 12.4×9.8×11.6cm in size, with regular edges and clear borders. T1WI showed slightly low signal, and T2WI showed mixed slightly high signal , DWI showed high signal intensity, irregular necrosis area was seen in the center of the lesion, and the enhancement scan showed obvious heterogeneous enhancement in the arterial phase, and slow and continuous enhancement in the portal vein and delayed phase. Signal, the larger one is about 2.0×1.5×1.1cm. After enhancement, the arterial phase is obviously enhanced, the portal venous phase is rapidly reduced, the delayed phase is low signal, and the DWI is obviously high signal. T...

Embodiment 2

[0046] The embodiment of the application provides the combined treatment effect and safety evaluation of case 2:

[0047] see figure 2 , figure 2 The results before and after treatment of case 2 provided in the embodiment of the present application.

[0048] The MR results on April 30, 2019 showed a tumor in the right lobe of the liver with a size of 9.4cm×8.3cm×10.7cm ( figure 2 A); On May 10, 2019, he received a tumor embolization therapy, and then gave the patient combined drugs for the treatment of massive liver cancer, receiving thymusfasin (1.6mg, once a day during hospitalization, subcutaneous injection) combined with vitamin C (100mL normal saline + vitamin C injection 3000mg, once a day during hospitalization, intravenous infusion, once a day during hospitalization), anti-PD-1 antibody (200mg / time, once every three weeks) and apatinib ( One piece each time, once a day) and S-1 (one piece each time, twice a day, taking 14 days and stopping for 7 days, 21 days as ...

Embodiment 3

[0051] The embodiment of the application provides the combined treatment effect and safety evaluation of case 3:

[0052] see image 3 , image 3 The results before and after treatment of case 3 provided in the embodiment of the present application.

[0053] The MR results on September 20, 2020 showed that there was a huge irregular mass in the S4 / 8 segment of the liver, with a size of about 4.7×4.5×4.2cm, with irregular edges and unclear boundaries. T1WI showed slightly low signal, and T2WI showed mixed Slightly hyperintensity, DWI showed hyperintensity, significantly heterogeneous enhancement in arterial phase of enhanced scan, portal vein decreased rapidly, and slightly hypointensity in delayed phase; no abnormality was found in portal vein and hepatic vein ( image 3 A). The patient was given combined drugs for the treatment of massive liver cancer, after thymofasin (1.6mg, once a day during hospitalization, subcutaneously injected) combined with vitamin C (100mL normal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicine combination, and particularly relates to a combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of a medicine for treating megaloblastic liver cancer. The combined medicine composition for treating megaloblastic liver cancer comprises thymalfasin, vitamin C, an anti-PD-1 antibody, apatinib and tegafur. The invention provides the combined medicine composition for treating megaloblastic liver cancer and application thereof in preparation of the medicine for treating megaloblastic liver cancer. On the premise of not carrying out TACE operation and conventional radiotherapy and chemotherapy, the volume of the tumor at the liver is effectively reduced, the growth of the liver tumor can be obviously inhibited, the illness state of the patient is relieved, even the intrahepatic metastasis, the serum thymidine kinase content and the alpha fetoprotein content are reversed to be restored to a normal range, and abnormal liver function and bone marrow function, toxic and side effects and adverse events are not caused.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a combined pharmaceutical composition for treating massive liver cancer and its application in the preparation of medicines for treating massive liver cancer. Background technique [0002] Primary liver cancer is the fourth most common malignant tumor in my country. Half of the patients are in the middle and late stages when they are diagnosed. The prognosis is poor and the average survival time is short. According to imaging results, massive liver cancer refers to a special type of liver cancer with a tumor diameter ≥ 5 cm. Because the tumor is huge, it is often located close to important areas such as the hilum of the liver, oppressing and invading large blood vessels inside and outside the liver, making surgery difficult; at the same time , the surgical resection range is large, and the risk of postoperative hepatic insufficiency is high. Therefore, how to choos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/22A61K39/395A61K45/06A61P1/16A61P35/00A61K31/375A61K31/444A61K31/506
CPCA61K39/3955A61K38/2292A61K31/375A61K31/444A61K31/53A61K31/44A61K31/513A61K45/06A61P35/00A61K2300/00
Inventor 赵建夫陈填烽陈敏锋陈文慧刘婷全强蓝丹孙智婷张焱聂诗情
Owner THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com